169677-21-8

Basic information

• Product Name: Benzenesulfonamide, N-[5-bromo-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- 4-(1,1-dimethylethyl)-
• CAS NO: 169677-21-8
• Molecular Formula: C21H24BrN5O4S2
• Molecular Weight: 554.489
• Mol File: 169677-21-8.mol

Chemical Properties

• CAS DataBase Reference: Benzenesulfonamide, N-[5-bromo-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- 4-(1,1-dimethylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonamide, N-[5-bromo-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- 4-(1,1-dimethylethyl)-(169677-21-8)
• EPA Substance Registry System: Benzenesulfonamide, N-[5-bromo-6-[2-[[5-(methylthio)-2-pyrimidinyl]oxy]ethoxy]-4-pyrimidinyl]- 4-(1,1-dimethylethyl)-(169677-21-8)

Safety Data

• Hazardous Substances Data: 169677-21-8(Hazardous Substances Data)

Upstream product

• 15084-51-2 4-tert-butylbenzenesulfonyl chloride 
• 169677-47-8 4-tert-butyl-N-(6-(2-hydroxyethoxy)-4-pyrimidinyl)benzenesulfonamide 
• 169677-46-7 4-tert-butyl-N-(6-chloro-4-pyrimidinyl)benzenesulfonamide 
• 6292-59-7 4-tert-butylbenzenesulphonamide 
• 115581-36-7 2-chloro-5-(methylsulfanyl)pyrimidine 
• 169677-48-9 N-(5-bromo-6-(2-hydroxyethoxy)-4-pyrimidinyl)-4-tert-butylbenzenesulfonamide 

Downstream Products

• 169678-58-4 4-tert-butyl-N-(5-(4-diethoxymethyl)phenyl-6-(2-((5-methylthio-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)benzenesulfonamide 
• 169679-65-6 4-tert-butyl-N-(5-(4-formyl)phenyl-6-(2-((5-methylthio-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)benzenesulfonamide 

Relevant articles and documents

Potent and selective ET-A antagonists. 1. Syntheses and structure-activity relationships of N-(6-(2-(aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide derivatives

Modifications to the ETA/B mixed type compounds 1 (Ro. 46-2005) and 2 (bosentan) were performed. Introduction of a pyrimidine group into 1 resulted in a dramatic increase in affinity for the ETA receptor, and the subsequent optimization of substituents on the pyrimidine ring led us to the discovery of N-(6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-5-(4-methylphenyl)- 4pyrimidinyl)-4-tert-butylbenzenesulfonamide (7k), which showed an extremely high affinity for the human cloned ETA receptor (Ki=0.0042±0.0038 nM) and an ETA/B receptor selectivity up to 29 000 (Ki=130±50 nM for the human cloned ETB receptor). The compound was designed on the hypothesis that the hydrogen atom of the hydroxyl group in 1 and 2 played a role not as a proton donor but as an acceptor in the possible hydrogen bonding with Tyr129. Since the incorporation of a pyrimidinyl group into the hydroxyethoxy side chain of the nonselective antagonist (1) dramatically enhanced both the ETA receptor affinity and selectivity, and since similar results were obtained from the benzene analogues, we put forward the hypothesis that a "pyrimidine binding pocket" might exist in the ETA receptor.

Sulfonamide derivative and process for preparing the same

Novel sulfonamide derivatives of the formula ?I!: STR1 wherein Ring A and Ring B are substituted or unsubstituted monocyclic, bicyclic or tricyclic hydrocarbon, or substituted or unsubstituted heterocyclic group, Q is single bond, --O--, --S--, --SO--, --

Benzenesulfonamide derivative and process for preparing thereof

A benzenesulfonamide derivative of the formula [I]: STR1 wherein Ring A and Ring B are the same or different and each substituted or unsubstituted benzene ring, Q is a single bond or a group of the formula: --O--, --S--, --SO--, --SO2 -- or --CH2--, Y is a group of the formula: --O--, --S-- or --NH--, Alk is lower alkylene group or lower alkenylene group, Z is a single bond or a group of the formula: --O-- or --NH--, R is a substituted or unsubstituted aromatic heterocyclic or aryl group, R1 is hydrogen atom, trifluoromethyl group, substituted or unsubstituted lower alkyl group, substituted or unsubstituted lower alkenyl group, mono-- or di-lower alkylamino group, substituted or unsubstituted lower alkylthio group, substituted or unsubstituted lower alkoxy group, substituted or unsubstituted lower alkynyl group, aromatic heterocyclic group, substituted or unsubstituted aliphatic heterocyclic group or aryl group, provided that when Z is a single bond, R is a substituted or unsubstituted aromatic heterocyclic group, or a pharmaceutically acceptable salt thereof, and processes for preparing the same, these compounds having endothelin antagonistic activity and being useful in the prophylaxis or treatment of various diseases caused by endothelin.